Equity Profile

PODD

Insulet Corporation

Health CareHealth Care Equipment$10.6B

May6Wed

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:00 AM EDT

Insulet Corporation Beats on EPS, Stock Down 9.7%

Metric	Actual	Expected	Surprise
EPS	$1.42	$1.19	+24.78%
Revenue	N/A	$730M	N/A

management commentary, guidance changes, and full analysis available with Pro.

Insulet Corporation Beats on EPS, Stock Down 9.7%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$1.42	$1.19	+24.78%
Revenue	N/A	$730M	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Insulet Corporation reported better-than-expected earnings per share, but the stock fell by 9.7% in response. The decline may be attributed to the lack of revenue information and guidance, leaving investors uncertain about future performance. Overall, the strong EPS surprise contrasts with the missing revenue details, which could have contributed to the negative stock reaction.

Company Snapshot

Insulet Corporation (PODD) is a healthcare company that specializes in developing and manufacturing innovative insulin delivery systems for people with diabetes. With a market cap of $12 billion, Insulet plays a crucial role in the health care equipment sector, focusing on improving the quality of life for diabetes patients through its Omnipod product line.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and will show how well Insulet is managing its costs and revenue.

$1.19

Revenue

Total revenue reflects the company's sales performance and growth trajectory, crucial for understanding market demand for its products.

$730M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+9.35%

Avg Stock Reaction

+1.69%

Last Quarter Recap

In Q4 2025, Insulet reported an EPS of $1.55, exceeding estimates by 4.87%, which led to a positive stock reaction of 4.76% the following day. However, revenue details were not disclosed, leaving some uncertainty about overall sales performance.

Management Promises & Guidance

Focus on expanding market share in the diabetes management space.
Commitment to innovation in product development.
Plans to enhance customer support and service.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Insulet's upcoming earnings, with expectations for solid EPS and revenue growth. However, there are concerns about potential market saturation and competition in the diabetes management sector.

Bull Case

If Insulet beats expectations, it could signal strong demand for its products and effective cost management, potentially driving the stock higher.

Bear Case

Conversely, if the company misses estimates, it may indicate challenges in sales or increased competition, leading to a negative market reaction.

Key Metrics to Watch

EPS

$1.19

Earnings per share is a key indicator of the company's profitability and will show how well Insulet is managing its costs and revenue.

Revenue

$730M

Total revenue reflects the company's sales performance and growth trajectory, crucial for understanding market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS meet or exceed the consensus estimate of $1.19?

A strong EPS could indicate effective cost management and robust demand for Insulet's products, which is crucial for investor confidence.

What are the revenue figures compared to the consensus of $730M?

Revenue performance will provide insight into the company's market position and growth potential, impacting future projections.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Insulet's growth potential given its recent product innovations and market expansion efforts. There is a strong chance that demand for its Omnipod systems is increasing faster than anticipated.

Supporting Evidence

Insulet has consistently beaten EPS estimates in recent quarters, suggesting strong operational performance.

The options market is pricing in a larger move than historical averages, indicating heightened expectations.

Recent product launches have received positive feedback, which may not be fully reflected in analyst estimates.

Key Risk

If revenue growth significantly exceeds $730M, it could challenge the current market outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched as it reflects Insulet's ability to navigate a competitive landscape while maintaining growth.

Bull Confirmed If

An EPS of $1.25 or higher with revenue exceeding $735M would confirm strong operational performance.

Bear Confirmed If

An EPS below $1.06 or revenue falling short of $713M would raise concerns about market demand and competition.

Pre-Earnings Positioning

Options Market

Implied Move

±11.73%

Historical Avg

±4.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±12.0% while PODD has averaged ±4.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

51.3%

Calls (8K)P/C Ratio: 0.62Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insulet beats expectations, history suggests the stock could rise by an average of 3.7%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline, with historical data indicating an average drop of 1.1% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the sales performance of the Omnipod product line.
2Any new partnerships or collaborations that could enhance market reach.
3Insights into cost management strategies and their impact on profitability.
4Feedback from customers regarding product satisfaction and usability.
5Management's outlook on future market trends and competitive landscape.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and will show how well Insulet is managing its costs and revenue.

$1.19

Revenue

Total revenue reflects the company's sales performance and growth trajectory, crucial for understanding market demand for its products.

$730M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+9.35%

Avg Stock Reaction

+1.69%

Last Quarter Recap

Management Promises & Guidance

Focus on expanding market share in the diabetes management space.
Commitment to innovation in product development.
Plans to enhance customer support and service.

Expectations

Wall Street Expectations

Bull Case

If Insulet beats expectations, it could signal strong demand for its products and effective cost management, potentially driving the stock higher.

Bear Case

Conversely, if the company misses estimates, it may indicate challenges in sales or increased competition, leading to a negative market reaction.

Key Metrics to Watch

EPS

$1.19

Earnings per share is a key indicator of the company's profitability and will show how well Insulet is managing its costs and revenue.

Revenue

$730M

Total revenue reflects the company's sales performance and growth trajectory, crucial for understanding market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS meet or exceed the consensus estimate of $1.19?

A strong EPS could indicate effective cost management and robust demand for Insulet's products, which is crucial for investor confidence.

What are the revenue figures compared to the consensus of $730M?

Revenue performance will provide insight into the company's market position and growth potential, impacting future projections.

Edge

What the Street Is Missing

Why consensus could be wrong

Supporting Evidence

Insulet has consistently beaten EPS estimates in recent quarters, suggesting strong operational performance.

The options market is pricing in a larger move than historical averages, indicating heightened expectations.

Recent product launches have received positive feedback, which may not be fully reflected in analyst estimates.

Key Risk

If revenue growth significantly exceeds $730M, it could challenge the current market outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched as it reflects Insulet's ability to navigate a competitive landscape while maintaining growth.

Bull Confirmed If

An EPS of $1.25 or higher with revenue exceeding $735M would confirm strong operational performance.

Bear Confirmed If

An EPS below $1.06 or revenue falling short of $713M would raise concerns about market demand and competition.

Pre-Earnings Positioning

Options Market

Implied Move

±11.73%

Historical Avg

±4.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±12.0% while PODD has averaged ±4.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

51.3%

Calls (8K)P/C Ratio: 0.62Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insulet beats expectations, history suggests the stock could rise by an average of 3.7%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline, with historical data indicating an average drop of 1.1% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the sales performance of the Omnipod product line.
2Any new partnerships or collaborations that could enhance market reach.
3Insights into cost management strategies and their impact on profitability.
4Feedback from customers regarding product satisfaction and usability.
5Management's outlook on future market trends and competitive landscape.